

Figure 1 (a) Painful, erosive lesions on the upper chest with peripheral tense blisters (insert). (b) Histological features showing dense neutrophil infiltration throughout the edematous dermis. (c) Higher magnification showed neutrophil infiltration. (d) MRI examination revealed edematous swelling on the right gluteus maximus muscle.

our knowledge, there have been no reports of neutrophilic myositis in association with bullous Sweet's syndrome. A previously reported case developed severe sterile neutrophilic myositis as the first manifestation of acute myelogenous leukemia.[6] In the present case, myositis was developed soon after admission, which occurred almost concurrently with cutaneous manifestations. Because of the increased risk of infection, we did not escalate the dose of prednisolone; however, muscle lesions were transient and gradually improved. Because muscle biopsy was not carried out, it is uncertain that the patient developed neutrophilic myositis during the course. Hematoma was unlikely, but other factor such as infection was not denied, because drainage procedures were not performed. In such cases as immunocompromised patients like ours, it is often difficult to decide whether other organ involvement is caused by aseptic neutrophilic infiltration or infection.

Conflict of interests

The authors declare no conflict of interests.

Bibliografía

1. Klinger S, Mathis N, Jackson S. Bullous Sweet syndrome associated with an aseptic splenic abscess. Cutis. 2009;84:255–8.
2. Mirouse A, Virone A, Gobert D, Soussan M, Braun T, Ziol M, et al. Aseptic muscular abscesses associated with myelodysplastic syndrome. Eur J Dermatol. 2014;24:696–7.
3. Cohen PR. Sweet's syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
4. Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol. 2006;55:1066–71.
5. Neoh CY, Tan AWH, Ng SK. Sweet's syndrome: a spectrum of unusual clinical presentations and associations. Br J Dermatol. 2007;156:480–5.
6. Marie I, Levesque H, Joly P, Reumont G, Courville P, Baudrimont M, et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol. 2001;44:137–9.

K. Sato, T. Miura, M. Ohtsuka, T. Yamamoto*

Department of Dermatology, Fukushima Medical University, Fukushima, Japan

*Corresponding author.
E-mail address: toyamade@fmu.ac.jp (T. Yamamoto).

https://doi.org/10.1016/j.ad.2017.07.012
0001-7310/

Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases

Riesgo de reactivación de la hepatitis B en los pacientes tratados con agentes anti-TNFα para enfermedades inflamatorias inmuno-mediadas

Dear Editor:

TNFα inhibitors revolutionized the treatment of immune-mediated inflammatory diseases (IMIDs). Due to their immunosuppressive nature, these therapies increase susceptibility for new infections and may alter the natural course of latent infections.[1,2]

Occult HBV infection is defined as the persistence of viral genome in the liver tissue of individuals serologically negative for HBV surface antigen (HBsAg).[3] Patients with positive antibodies to HBV core antigen (anti-HBc) and negative HBsAg and HBV-DNA, with or without antibodies to HBV surface antigen (anti-HBs) are potential occult HBV carriers[3] and may reactivate under immunosuppressive therapy.[1,2] Studies in subjects with past HBV infection treated with anti-TNFα therapy for inflammatory bowel disease (IBD) and rheumatic diseases estimated a reactivation rate between 1.7% and 5% of patients.[1,2]

The aim of this retrospective study was to evaluate the rate of reactivation in anti-HBc positive/HBsAg negative patients treated with TNFα inhibitors for psoriasis, rheumatologic diseases and IBD.

Patients treated with TNFα inhibitors for IMIDs from January 2000 to December 2014, for at least one month were retrospectively included. Information regarding patients' HBV screening serology (HBsAg, anti-HBc and anti-HBs antibodies) and HBV-DNA (in anti-HBc positive patients) prior to the initiation of TNFα inhibitors as well as HBsAg seroconversion, HBV-DNA *de novo* detection and ALT/AST levels during anti-TNF therapy were collected. HBV reactivation was defined as titer elevation up to 2–3 times the upper limit of normal ALT, in combination with *de novo* detection of HBV-DNA or HBsAg seroconversion. Furthermore, patients' demographic, clinical and therapeutic characteristics were recorded. This study was approved by the hospital's Institutional Review Board.

From 389 patients treated with TNFα inhibitors during the study period, 26 (9%) patients were anti-HBc positive/HBsAg negative and one patient presented with a serologic profile compatible with chronic hepatitis B. The mean observation time was 43.6 ± 28.7 months. Subjects' demographic and clinical data are reported in Table 1. Nineteen (73.1%) patients were anti-HBs positive in the pre-treatment screening. HBV-DNA levels were available in 7 (26.9%) patients, being undetectable in all of them. Additionally, during follow-up, HBV-DNA levels were measured in 7 additional patients (that had not been measured before treatment) amounting to 53.8% patients with undetectable HBV-DNA levels. In these patients, HBV-DNA levels were measured every 6months for a 2-years period. No rise of the aminotransferases values was observed in any patient during follow-up. At the end of the observational period, no case of reactivation was observed regardless of anti-HBs positivity.

Patients with past HBV infection (anti-HBc positive/HBsAg negative patients) can arbor an occult infection, and be susceptible to reactivation when exposed to immunosuppression, including TNFα inhibitors. This risk is highly depends on the agent's target and mechanism of action.[4,5] Although it is accepted that TNFα inhibitors may lead to HBV reactivation in these patients, the reactivation rates are much lower when compared to HBsAg positive patients.[1] The prevalence of patients with past HBV (9%) found in this study was similar to other published studies in patients with IMIDs.[6] A systematic review including 168 anti-HBc positive/HBsAg negative patients with RA, spondyloarthropathies, psoriasis and IBD found HBV reactivation 5.4% of patients[1] while a meta-analysis including 468 anti-HBc positive/HBsAg negative patients treated with TNFα inhibitors for rheumatologic diseases, HBV reactivation was observed in 1.7% with a percentage of HBV reactivation ranging from 0 to 8.3%.[2] As seen in other studies, including with patients with psoriasis, no cases of HBV reactivation were observed in this study.[7,8]

All patients that had HBV DNA measured during screening, maintained their levels below detection threshold during follow-up (measured every 6 months for 2 years and then yearly). However, detectable baseline viral loads have been found in this subset of patients.[9]

The title of anti-HBs may influence the risk of reactivation of HBV.[9] In this study, 73.1% patients were anti-HBs positive in the pre-treatment screening, and may have been important decreasing the risk of HBV reactivation.

Table 1 Baseline characteristics of 26 anti-HBc positive/HBsAg negative patients.

Patients	26 (100%)
Female gender, N (%)	10 (38.5)
Age in years, mean ± SD	52.65 ± 14.12
Disease duration in years, mean ± SD	19.16 ± 11.92
CD, *N* (%)	9 (34.6)
RA, *N* (%)	4 (15.4)
AS, *N* (%)	4 (15.4)
Ps + PsA, *N* (%)	6 (23.1)
Ps, *N* (%)	3 (11.5)
Therapy	
Anti-TNFα, *N* (%)	26 (100)
Etanercept, *N* (%)	12 (46.2)
Adalimumab, *N* (%)	8 (30.8)
Infliximab, *N* (%)	6 (23.1)
Switch, *N* (%)	7 (26.9)
Combined therapy, *N* (%)	13 (50)
MTX, *N* (%)	7 (26.9)
AZA, *N* (%)	4 (15.4)
CsA, *N* (%)	1 (3.8)
CS, *N* (%)	4 (15.4)
Treatment duration in years	
Etanercept	3.1
Adalimumab	4.2
Infliximab	4.9

CD, Chron's disease; RA, rheumatoid arthritis; AS, ankylosing spondylitis; Ps, psoriasis; PsA, psoriatic arthritis; TNF, tumor necrosis factor; MTX, methotrexate; AZA, azathioprine; CsA, cyclosporine A; CS, corticosteroids.

The main limitation of this study is its retrospective nature and the small and heterogenic sample, the long period of inclusion (as intra-hospital and international recommendations has changed along time) and the inexistence of HBV DNA data for some of the anti-HBc positive/HBsAg negative patients (preventing to determine HBV occult infection).

Current guidelines state that candidates for chemotherapy and immunosuppressive therapy who are anti-HBc positive/HBsAg negative, regardless of anti-HBs status and with undetectable serum HBV-DNA should be followed carefully by means of ALT and HBV-DNA testing and treated with nucleotide analogs therapy only upon confirmation of HBV reactivation before ALT elevation.[10]

Treatment with anti-TNFα agents is safe in anti-HBc positive/HBsAg negative patients. HBV reactivation is probably related to the presence of HBV in circulation rather than to the serologic status of previous exposure. Nonetheless, and as expressed in current guidelines, screening for HBV serologic markers prior to initiation of anti-TNFα therapy is of major importance since it may dictate if prophylactic treatment, vaccination or monitoring should be taken to minimize the risks related to hepatitis B flare/reactivation.

Conflict of interests

Rui Pereira, Inês Lobo and Filipe Nery have no conflicts of interest to disclosure.

Tiago Torres has participated in clinical trials sponsored by AbbVie, Amgen, and Novartis and has received honoraria for acting as a consultant and/or as a speaker at events sponsored by AbbVie, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Eli-Lilly, MSD, Novartis, and Pfizer.

Acknowledgments

The authors thank Raquel Faria, MD and Paula Lago, MD the important collaboration in this study.

Bibliografía

1. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, et al. Hepatitis B virus reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–71.
2. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–21.
3. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056–75.
4. Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification. World J Hepatol. 2015;7:825–30.
5. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol. 2014;2014:926836.
6. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.
7. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352–5.
8. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:179.
9. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–25.
10. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.

R. Pereira[a], I. Raposo[b], F. Nery[a,c], T. Torres[a,b,*]

[a] *Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal*
[b] *Department of Dermatology, Centro Hospitalar do Porto, Portugal*
[c] *Hepato-Pancreatic Unit, Centro Hospitalar do Porto, Porto, Portugal*

* Corresponding author.
E-mail address: torres.tiago@outlook.com (T. Torres).

https://doi.org/10.1016/j.ad.2017.07.011
0001-7310/

Aspergilosis cutánea secundaria pustulosa en paciente inmunosuprimido

Pustular Secondary Cutaneous Aspergillosis in an Immunosuppressed Patient

Sra. Directora:

Con el incremento de las terapias inmunosupresoras, debido a procedimientos como el trasplante renal o la poliquimioterapia intensiva para el tratamiento de las neoplasias, en los últimos años se ha incrementado notablemente las infecciones oportunistas por hongos[1,2]. *Aspergillus* es un hongo filamentoso oportunista ubicuo, que se encuentra con frecuencia en el suelo, en sustancias orgánicas en descomposición e incluso en restos alimentarios[2]. Suele incrementarse su número en condiciones de movilización de polvo, de manera que es especialmente abundante durante las obras de construcción y mantenimiento, principalmente en hospitales[2]. Por este motivo, es importante evitar la exposición de los pacientes con inmunosupresión y riesgo de infección a lugares en obras y con humedad. *Aspergillus* puede producir infecciones graves con afectación primaria o secundaria de la piel[3]. Presentamos un caso clínico de aspergilosis cutánea con morfología ampollar.

Un paciente de 56 años en seguimiento por mieloma múltiple IgA desde los últimos 4 años, estadio IIIA, es valorado por presentar lesiones cutáneas indoloras nodulares de más de 1 cm y una gran ampolla de reciente aparición en el codo izquierdo. El paciente había recibido múltiples tratamientos para su neoplasia incluyendo quimioterapia con bortezomib 1,3 mg/m^2 cada 4 días 4 ciclos en total, ciclofosfamida 500 mg en 3 días espaciados una semana y durante